|Values are valid only on day of printing.|
Updated: June 2013
The CellSearch Circulating Tumor Cell (CTC) test is a simple blood test that helps oncologists in assessing the prognosis of patients with metastatic breast, colorectal, or prostate cancer. The CellSearch test is the only FDA-approved test for CTC assessment. Each result of the CellSearch test performed at Mayo Clinic is verified by both a cytotechnologist and a pathologist to ensure quality. In addition, Mayo Clinic pathologists and scientists are always available for consultation.
Studies have demonstrated CTCs can play an important role as an adjunct to imaging. (1-3) These studies demonstrate that metastatic breast cancer patients with ≥5 CTCs and imaging findings that show a stable/partial response have a shorter overall survival than those patients with <5 CTCs and imaging findings that show a stable/partial response. This is an indication that rising CTC levels occur before imaging can detect a possible change in patient status.
Studies suggest that the CellSearch test is able to detect tumor recurrence in metastatic breast cancer patients before tumor recurrence is detected by imaging. (4) This may help oncologists switch to more effective therapies.